Results 221 to 230 of about 127,271 (293)
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
ABSTRACT Background Managing febrile neutropenia is challenging due to the limited sensitivity of blood culture (BC) and the lack of tools differentiating infectious from non‐infectious fever. T2 magnetic resonance (T2MR) is a culture‐independent system detecting bacteria (T2Bacteria) and yeasts (T2Candida); SeptiCyte RAPID is a host response assay ...
Anna Maria Peri +6 more
wiley +1 more source
Electro-encephalographic surrogate measures fail to describe the pharmacodynamic interaction between ketamine and propofol. [PDF]
Mortier, Eric +2 more
core +1 more source
Abstract Background Evidence for optimal location of subpalpebral lavage (SPL) systems is lacking. Objectives To compare the rate and types of complications with SPL systems located in central upper‐ compared with medial lower‐eyelid in hospitalised patients. Study Design Prospective, randomised treatment trial.
Annabelle E. Graham +2 more
wiley +1 more source
Sustained Release of Ciprofloxacin Hydrochloride and Loteprednol Etabonate from Ophthalmic Ocuserts for Treatment of Bacterial Conjunctivitis [PDF]
Swati Mayur Keny, Leena Sawaikar
openalex +1 more source
ABSTRACT Aim To evaluate the real‐world comparative effectiveness of various adjunctive systemic antibiotic regimens in combination with scaling and root planing (SRP) using a large, multi‐centre retrospective cohort. Materials and Methods Electronic health records were used retrospectively to categorise periodontitis patients into ‘SRP Only’ or ‘SRP +
Georgios S. Chatzopoulos, Larry F. Wolff
wiley +1 more source

